Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
ClinicalTrials.gov study NCT04578106. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
ClinicalTrials.gov study NCT03280563. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
ClinicalTrials.gov study NCT00270894. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer
ClinicalTrials.gov study NCT01461044. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
ClinicalTrials.gov study NCT01669252. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
ClinicalTrials.gov study NCT03556358. IPD Sharing: NO. Countries: 10. Publications: 0.
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
ClinicalTrials.gov study NCT00194779. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01111825. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Meta
ClinicalTrials.gov study NCT00721630. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
ClinicalTrials.gov study NCT04659499. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
ClinicalTrials.gov study NCT04499924. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
ClinicalTrials.gov study NCT06374459. IPD Sharing: YES. Countries: 1. Publications: 0.
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
ClinicalTrials.gov study NCT02683083. IPD Sharing: NO. Countries: 1. Publications: 0.
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
ClinicalTrials.gov study NCT02061085. IPD Sharing: Not stated. Countries: 1. Publications: 0.
MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC
ClinicalTrials.gov study NCT03881605. IPD Sharing: YES. Countries: 1. Publications: 0.
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
ClinicalTrials.gov study NCT05091528. IPD Sharing: NO. Countries: 1. Publications: 0.
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
ClinicalTrials.gov study NCT00567879. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
ClinicalTrials.gov study NCT01855828. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
ClinicalTrials.gov study NCT05744375. IPD Sharing: NO. Countries: 1. Publications: 0.
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
ClinicalTrials.gov study NCT03321981. IPD Sharing: NO. Countries: 7. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.